SLDB
Solid Biosciences Inc.5.82
+0.11+1.93%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
453.44MP/E (TTM)
-Basic EPS (TTM)
-2.48Dividend Yield
0%Recent Filings
8-K
Promising SGT-003 trial data
Solid Biosciences unveiled promising interim data from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, showing mean 58% microdystrophin expression and 51% positive fibers at Day 90 in 10 pediatric participants, alongside strong correlations to DAPC restoration and 34% mean CK reduction signaling muscle protection. SGT-003 proved generally well-tolerated with steroids alone, while cardiac markers trended toward normal LVEF and 31% troponin drop. Enrollment hits 23 dosed; 30 expected by early 2026 before FDA talks on accelerated paths. One SAE resolved swiftly.
10-Q
Q3 FY2025 results
Solid Biosciences ramped up R&D spending in Q3 FY2025 ended September 30, 2025, posting a $45.8M net loss, up 39.9% y/y from $32.7M, driven by higher SGT-003 clinical and manufacturing costs while SGT-212 expenses dipped post-acquisition. YTD net loss widened to $124.5M from $82.1M y/y, with operating expenses climbing 44.5% to $129.8M on expanded trials for neuromuscular and cardiac candidates. Cash burn quickened to $102.7M YTD from $70.4M, yet a February 2025 offering bolstered liquidity to $236.1M, funding operations into mid-2027. The FA212 asset acquisition closed in September 2024 for $1.0M upfront plus milestones, recognizing $5.1M in R&D expense. Derivative liabilities from contingent payments rose to $6.6M, contributing to the net-operating gap. Competition from established gene therapies like Sarepta's ELEVIDYS pressures market entry.
10-Q
Q2 FY2025 results
Solid Biosciences posted a Q2 net loss of $39.5M, up 57.5% y/y from $25.1M, driven by R&D expenses surging 66.6% to $32.4M on ramped SGT-003 manufacturing and clinical costs, while G&A rose 11.4% to $9.3M. YTD net loss widened to $78.8M from $49.4M, with operating loss at $81.7M versus $54.7M last year; EPS improved to $(0.42) from $(0.61) y/y but reflects anti-dilution from 35.7M new shares in February's $188M offering. Cash swelled to $268.1M, funding ops into mid-2027, yet derivative liabilities tied to SGT-212 milestones jumped to $5.7M. SGT-003 dosing hit 15 patients in INSPIRE DUCHENNE, showing tolerability. Pipeline advances with IND clearances for SGT-212 and SGT-501. Regulatory hurdles loom large.
8-K
Stockholders approve share increases
Solid Biosciences stockholders approved key amendments at the June 12, 2025 annual meeting, doubling authorized common shares to 240 million and adding 9 million shares to the 2020 Equity Incentive Plan while tweaking its evergreen provision to 6% starting 2026. They elected Alexander Cumbo and Sukumar Nagendran as Class I directors through 2028, ratified PwC as auditors, and backed executive pay. This bolsters flexibility for future equity grants. Yet dilution looms.
8-K
Expands stock offering to $85M
Solid Biosciences Inc. filed a prospectus supplement on May 15, 2025, expanding its at-the-market offering to up to $85.0 million in common stock shares under an amended sales agreement with Jefferies LLC. This boosts the prior $75.0 million program, where $10.5 million in gross proceeds were already raised. The move provides flexible capital access. No further sales will occur under the old prospectus.
DSGN
Design Therapeutics, Inc.
9.62+0.50
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RGNX
REGENXBIO Inc.
14.11+0.28
RNA
Avidity Biosciences, Inc.
71.97+0.11
SGMT
Sagimet Biosciences Inc. - Seri
6.05+0.02
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
SNTI
Senti Biosciences, Inc.
1.25+0.04
SRPT
Sarepta Therapeutics, Inc.
22.31+0.76
TRDA
Entrada Therapeutics, Inc.
11.37+0.34
VYGR
Voyager Therapeutics, Inc.
4.42+0.06